Ideaya Biosciences and Servier announce data from three uveal melanoma trials at ESMO 2026

IDYA•2026-10-19

Ideaya Biosciences and Servier announced data from three clinical trials supporting the potential of darovasertib as a therapy for patients across the uveal melanoma treatment journey.

1. Trial data announcement

Ideaya Biosciences and Servier announced data from three clinical trials at ESMO 2026, saying the findings support the potential of darovasertib to become a foundational therapy for patients across the uveal melanoma treatment journey.

Ideaya Biosciences and Servier announce data from three uveal melanoma trials at ESMO 2026

1. Trial data announcement

Related News

Cardinal Infrastructure raises cash portion of Hughes Brothers acquisition to 60%

Knox and Palantir partner to accelerate software delivery through largest federal cloud

Insmed launches Brinsupri 25 mg tablets in Japan for bronchiectasis

Morgan Stanley cuts Las Vegas Sands target price to $55 from $61

KKR to sell railcar-leasing company Infinity to Ares for $2.9 billion